Christoph Uleer
A5020142852- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- DNA Repair Mechanisms
- Biosimilars and Bioanalytical Methods
- Cancer survivorship and care
- Glutathione Transferases and Polymorphisms
- PI3K/AKT/mTOR signaling in cancer
- Management of metastatic bone disease
- Chronic Lymphocytic Leukemia Research
- Global Cancer Incidence and Screening
- Ferroptosis and cancer prognosis
University of Hildesheim
2016-2025
Orthopädische Praxis
2021-2024
Berufsverband der Frauenärzte
2024
Klinik für Frauenheilkunde
2018-2023
Intelligent Transport Systems Niedersachsen
2023
Praxis
2010-2022
Martin Luther University Halle-Wittenberg
2017-2022
University Hospital Heidelberg
2016-2019
Heidelberg University
2016-2019
Universitäts Frauenklinik
2019
Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast International 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression. Methods Patients with HER-2–positive cancer that progresses during were randomly assigned to receive capecitabine (2,500 mg/m body-surface area on days 1 through 14 [1,250 semi-daily]) alone or continuation of (6...
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment human epidermal growth factor receptor 2–negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more following: pT greater than 2, grade 2 3, high urokinase-type plasminogen activator/plasminogen activator...
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results higher pCR rates uncertain survival impact. We evaluated gemcitabine a backbone as short 12-week A-free focus on early response.Patients TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor 2-negative,...
Breast cancer tumors are known to be highly heterogeneous and differences in their metabolic phenotypes, especially at protein level, less well-understood. Profiling of metabolism-related proteins harbors the potential establish new patient stratification regimes biomarkers promoting individualized therapy. In our study, we aimed examine relationship between metabolism-associated expression profiles clinicopathological characteristics a large cohort breast patients. specimens from 801...
Phosphatidylinositide-3-kinase (PI3K) regulates proliferation and apoptosis; somatic PIK3CA-mutations may activate these processes. Aim of this study was to determine the prevalence in a cohort early stage breast cancer patients association course disease.From an unselected 1270 (PiA, Prognostic Assessment routine application, NCT01592825) 1123 tumours were tested for three PIK3CA hotspot-mutations H1047R, E545K, E542K by qPCR. Primary objectives their tumour characteristics. Secondary...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Abstract Backgound: The GeparOLA study evaluated paclitaxel(P) plus olaparib(O) in neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer (eBC) homologous recombination deficiency (HRD). HRD was defined by high HRD-score or germline(g)/tumor(t) BRCA1/2 mutations (g/tBRCA1/2mut). Here, we report long-term outcome data. Patients and Methods: (NCT02789332) a randomized, multicenter, prospective, open-label, phase II trial. eBC, HRD, indication (cT2-cT4a-d cT1c cN+...
<p>Supplementary figure 2: Distribution of RAD51 and γH2AX continue values</p>
<p>Supplementary figure 3: Multivariable logistic model to evaluate pCR using sTILs with 30% cut-off</p>
<p>Supplementary figure 1: Immunofluorescence images showing geminin-positive cells with and without RAD51 foci</p>
<div>AbstractPurpose:<p>The randomized GeparOLA trial reported comparable pathologic complete response (pCR) rates with neoadjuvant treatment containing olaparib versus carboplatin. In this study, we evaluate the association between functional homologous recombination deficiency (HRD) by RAD51 foci and pCR potential of improving patient selection combining stromal tumor-infiltrating lymphocytes.</p>Patients Methods:<p>This is a <i>post hoc</i> blinded...
<p>Supplementary figure 4: Disease-free survival according to treatment and RAD51</p>
Anthracycline-containing neoadjuvant chemotherapy (NACT) is the standard treatment for early triple-negative breast cancer (eTNBC); however, it associated with substantial toxicity. We performed whole transcriptome profiling of baseline tumor biopsies to identify gene networks predictive and prognostic pathological complete response (pCR) survival after de-escalated, anthracycline-free NACT in WSG-ADAPT-TN trial (NCT01815242). eTNBC patients (cT1c-cT4c, cN +) were randomized 12 weeks...
506 Background: The efficacy and toxicity of olaparib in early BC pts with homologous DNA repair deficiency (here defined as HRD score high tumors +/- germline (g) or tumor (t) BRCA mutation) is not well described. GeparOLA investigates HER2 negative HRD. Methods: (NCT02789332) randomized 102 to either paclitaxel 80 mg/m² weekly (Pw) plus 100 mg twice daily for 12 weeks (PwO n = 65) Pw carboplatin (Cb) AUC2 (PwCb 37), both followed by EC. Randomization was stratified hormone receptor-status...
In the neoadjuvant WSG-ADAPT-TN trial, 12-week nab-paclitaxel + carboplatin (nab-pac/carbo) was highly effective and superior to gemcitabine (nab-pac/gem) in triple-negative breast cancer regarding pathological complete response (pCR). Predictive markers for deescalated taxane/carbo use TNBC need be identified. Patients received 4 × nab-pac 125 mg/m2 (plus carbo AUC2 or gem 1,000 d1,8 q21). Expression of 119 genes PAM50 scores by nCounter were available 306/336 pretherapeutic samples....